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Abstract
Background: Acute exacerbations of idiopathic pulmonary fibrosis are major causes of morbidity and mortality
among patients with idiopathic pulmonary fibrosis. However, acute exacerbations remain unpredictable. The aim of
this study was to investigate risk factors for acute exacerbations of idiopathic pulmonary fibrosis.
Methods: We performed a retrospective cohort study of patients with idiopathic pulmonary fibrosis who visited
our institutions from January 1999 to September 2014. We investigated risk factors for acute exacerbations in
patients with idiopathic pulmonary fibrosis diagnosed retrospectively based on the official 2011 idiopathic
pulmonary fibrosis ATS/ERS/JRS/ALAT Update Statement.
Results: The idiopathic pulmonary fibrosis study cohort included 65 subjects. The median follow-up period was 2.
6 years. During follow-up, 24 patients (36.9 %) experienced acute exacerbations. A Kaplan-Meier curve
demonstrated that the 1-year, 2-year, and 3-year incidences of acute exacerbation were 9.6, 19.2 and 31.0 %,
respectively. Acute exacerbation exerted a significant impact on overall survival among those with the disease. A
log-rank test showed that baseline cardiovascular diseases, higher GAP (gender, age, physiology) stage (≥II), higher
serum lactate dehydrogenase level (≥180 U/L), higher serum surfactant protein-D level (≥194.7 ng/mL), higher
neutrophil (≥1.77 %) and eosinophil (≥3.21 %) percentages in bronchoalveolar lavage fluid samples, and treatment
with an immunosuppressive agent after diagnosis were associated with poor acute exacerbation-free probability. In
the Cox analysis adjusted for treatment with an immunosuppressive agent, baseline cardiovascular diseases, higher
GAP stage (≥II), and higher eosinophil percentage (≥3.21 %) in bronchoalveolar lavage fluid samples were
predictors of an acute exacerbation of idiopathic pulmonary fibrosis.
Conclusions: This study demonstrated that baseline cardiovascular diseases, higher GAP stage (≥II), and higher
eosinophil percentage (≥3.21 %) in bronchoalveolar lavage fluid samples were associated with the onset of an
acute exacerbation of idiopathic pulmonary fibrosis.
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Background
Idiopathic pulmonary fibrosis (IPF) is the most common
form of idiopathic interstitial pneumonia [1, 2], and the
median survival from the time of diagnosis is approxi-
mately 3 years [2]. The clinical course of individual pa-
tients with IPF is highly variable and unpredictable. IPF
is not a uniform, clinically dynamic disease; there is a
wide spectrum of disease courses, including stability or
slow progression over a period of years, rapid deterior-
ation, and even periods of relative stability punctuated
by events causing rapid decline [3–5]. This acute wors-
ening of the disease is sometimes attributed to identifi-
able conditions such as pneumonia and heart failure.
However, many of these events occur without an identi-
fiable cause, and are called acute exacerbations (AEs) of
IPF [4]. AE-IPF is a major cause of morbidity and mor-
tality in patients with IPF [3, 6–8]. In 553 Japanese pa-
tients with IPF, the most common cause of death was
AE with a frequency of 40 % [8], which was similar to
the 46 % value found in a previous study by Jeon and co-
workers in Korea [6]. There is no proven treatment for
AE-IPF. Patients with AEs have poor outcomes, with
mortality exceeding 60 % during hospital admission;
among those who survive, there is >90 % mortality
within 6 months after discharge [3, 4]. Therefore, eluci-
dating the pathogenesis of AE-IPF and predicting AE are
important and challenging issues.
Kondoh et al. reported that a higher body mass index,
higher modified Medical Research Council scale score,
and decline in forced vital capacity (FVC) at 6 months
after the diagnosis of IPF were independent risk factors
for AE-IPF [7]. In one study, a comparison of clinical
features between IPF patients with and without an AE-
IPF showed no difference in age, smoking status, oxy-
genation, or lung function at the time of diagnosis
[9]. Risk factors for AE-IPF reported by Song et al.
[3] include a lower FVC at baseline as well as never
having smoked. Pulmonary hypertension at baseline
was also reported to be associated with a significant
risk of a subsequent AE-IPF [10]. More recently,
Kondoh et al. reported that a rapid decline in vital
capacity percentage (≥10 % within 6 months after the
diagnosis of IPF) and high baseline alveolar-arterial
difference in oxygen (A-a DO2) value might be risk
factors for an AE-IPF over the 52 weeks of the study
[11]. However, studies regarding risk factors for AE-
IPF are still limited, and AEs remain unpredictable. In
addition, serum biomarkers and cellular analyses of
bronchoalveolar lavage (BAL) fluid are still of unclear
predictive value for AE-IPF. Furthermore, in most
previous studies investigating risk factors for AE-IPF,
the diagnosis of IPF was made based on diagnostic
criteria developed before the official IPF ATS/ERS/
JRS/ALAT Update Statement in 2011 [2].
The aim of this study was to investigate risk factors for
AE-IPF, focusing on the significance of serum markers
and cellular analyses of BAL fluid in patients with IPF
who were diagnosed based on the official 2011 IPF ATS/
ERS/JRS/ALAT Update Statement [2].
Methods
Study population
We performed a retrospective cohort study of patients
with IPF who visited Nagasaki University Hospital,
Nagasaki, Japan, or University Hospital of Occupational
and Environmental Health, Kitakyushu, Japan, from
January 1999 to September 2014. Diagnoses were made
retrospectively according to the official ATS/ERS/JRS/
ALAT statement [2]. Patients with underlying connective
tissue disease, occupational or environmental exposure,
or a histopathologic pattern on surgical lung biopsy
other than usual interstitial pneumonia (UIP) were ex-
cluded from the study. At our institution, patients with
suspected IPF routinely underwent bronchoscopy with
BAL at the time of initial diagnosis, unless the patient’s
status contraindicated to the need for bronchoscopy. Pa-
tients whose initial manifestation was an AE, patients
without initial BAL fluid evaluations, and patients lost to
follow-up within 90 days were excluded. Twelve of 65
(18.5 %) IPF diagnoses were confirmed pathologically in
multiple lobes by open lung biopsy or video-assisted
thoracoscopic surgery. AE-IPF was defined using the fol-
lowing previously reported criteria with a slight modifi-
cation: (1) a previous diagnosis of IPF; (2) unexplained
worsening of dyspnea within the past 30 days; (3) high-
resolution computed tomography (HRCT) with new
findings of bilateral ground-glass opacity or consolida-
tion; and (4) the absence of an alternative explanation
such as infection, pulmonary embolism, pneumothorax,
or heart failure [2, 4]. The study protocol was approved
by the Institutional Review Boards of Nagasaki Univer-
sity Hospital and University Hospital of Occupational
and Environmental Health. The patients’ approval or in-
formed consent was not required for a retrospective re-
view of their records, pursuant to the ethical guidelines
of the Japanese Ministry of Health, Labor, and Welfare.
Covariates
Data regarding patient characteristics were collected
from clinical notes recorded at the time of the initial
diagnosis of IPF and included age, sex, smoking history,
partial pressure of oxygen in arterial blood (PaO2)/frac-
tion of inspired oxygen (FiO2) ratio (P/F ratio), A-a DO2,
hematologic data, pulmonary function tests, and BAL
fluid cellular constituents. Data regarding serum concen-
trations of C-reactive protein (CRP), lactate dehydrogen-
ase (LDH), Krebs von den Lungen-6 (KL-6), and
surfactant protein (SP)-D were also collected from clinical
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notes recorded at the time of diagnosis. Gender-Age-
Physiology (GAP) stage and composite physiologic index
(CPI) were calculated as described previously [12, 13].
BAL and cell preparation
Bronchoscopy and BAL were performed as described
previously [14].
Clinical and outcome assessments
In the AE analysis, subjects were censored if they (1)
had not experienced an AE by September 30, 2014, or
(2) were lost to follow-up. In the survival analysis, sub-
jects were censored if they (1) were still alive on Septem-
ber 30, 2014, or (2) lost to follow-up. AE-free probability
and survival probability were calculated from the time of
the initial IPF diagnosis to censoring.
Statistical analysis
Baseline characteristics including demographics, baseline
pulmonary function, respiratory parameters, hematologic
data, serum markers, and BAL fluid findings were com-
pared between patients who experienced an AE during
the study period and those who did not. Data are de-
scribed as frequencies for categorical variables and as
the median and interquartile range (IQR) for quantita-
tive variables. Associations between variables were
assessed with Fisher’s exact test for categorical variables
and Wilcoxon’s rank-sum test for quantitative variables.
The cumulative AE incidence was estimated with the
Kaplan-Meier method. The association between survival
probability and AE was evaluated by the log-rank test. A
log-rank test was used to evaluate associations among
smoking status, cardiovascular diseases, GAP stage, bio-
markers (LDH, KL-6, and SP-D), BAL fluid cellular pro-
files (percentages of lymphocytes, neutrophils, and
eosinophils), treatment after diagnosis, and AE-free
probability because the test is a simple method that did
not require satisfying some assumptions. Cox’s propor-
tional hazards regression models were used to evaluate
hazard ratios (HRs) and adjust confounders. It was con-
sidered appropriate to determine a cut-off level instead
of using continuous data because some factors did not
satisfy the assumption that the log hazard increased
linearly with the covariate. The optimum cut-off values
for predicting AE incidence at the 3-year follow-up were
determined by maximizing the Youden index [15] calcu-
lated from a time-dependent receiver operating charac-
teristic (ROC) analysis with the R package timeROC
[16]. We reported the results at the 3-year follow-up, as
this was the interval with the most dramatic relationship
between biomarkers, BAL fluid cellular profiles, and AE
incidence. We evaluated HRs, 95 % confidence intervals
(95 % CIs), and P values for each factor with an un-
adjusted Cox analysis. Because of the small number of
AEs and deaths included in this study, it was considered
inappropriate to adjust more than two factors in a mul-
tiple Cox analysis to evaluate the relative hazards of AE
and death. Accordingly, we adjusted for treatment with
an immunosuppressive agent in the multiple Cox ana-
lysis, which was found to be a significant risk factor for
an AE-IPF in the log-rank test and unadjusted Cox
analysis in this study. All tests were two-sided, and a
P value less than 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA)
and R version 3.1.0.
Results
Subject characteristics
The IPF study cohort included 65 subjects. There were
51 men and 14 women with a median age of 69 years
(IQR, 62 to 73 years). There were 13 never smokers, 42
former smokers, and 10 current smokers. The median
follow-up period was 2.6 years (IQR, 1.3 to 4.2 years).
The median survival time (MST) for all subjects was
4.5 years from the time of the initial visit.
AE incidence
During the follow-up period, 24 patients (36.9 %) experi-
enced AEs. Eighteen patients (27.7 %) were lost to
follow-up. The Kaplan-Meier curve demonstrated that
the 1-year, 2-year, and 3-year incidences of AE-IPF were
9.6, 19.2 and 31.0 %, respectively (Fig. 1).
Demographic, physiological, gas exchange, and
laboratory data and BAL fluid findings between patients
with an AE (AE group) and those without an AE (Non-AE
group)
No significant differences were observed in sex or age
distributions between the groups. Patients who experi-
enced an AE had a lower total lung capacity than those
in the Non-AE group. Gas exchange and laboratory data
and BAL fluid findings were similar between the groups
(Table 1).
Impact of AE on overall survival
AE exerted a significant impact on overall survival in
IPF. There was a significant difference in survival be-
tween patients who experienced an AE (MST, 2.8 years)
and those who did not (MST, not calculable) (log-rank
test, P < 0.001) (Fig. 2).
Risk factors for AE
According to the ROC curve analysis, the optimum cut-
off levels to predict an AE-IPF were 180 U/L for LDH,
946 U/mL for KL-6, 194.7 ng/mL for SP-D; and 10.15
1.77 and 3.21 % for lymphocyte, neutrophil, and eosino-
phil percentages in BAL fluid samples, respectively. A
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log-rank test showed that baseline cardiovascular dis-
eases, higher GAP stage (≥II), higher serum LDH level
(≥180 U/L), higher serum SP-D level (≥194.7 ng/mL),
higher neutrophil (≥1.77 %) and eosinophil (≥3.21 %)
percentages in BAL fluid samples, and treatment with an
immunosuppressive agent after diagnosis were associ-
ated with poor AE-free probability (P = 0.042, 0.002,
0.048, 0.014, 0.048, 0.009, and 0.009, respectively)
(Table 2). In the unadjusted Cox analysis, treatment with
an immunosuppressive agent, baseline cardiovascular
diseases, higher GAP stage (≥II), higher serum SP-D
level (≥194.7 ng/mL), and a higher eosinophil percentage
in BAL fluid samples (≥3.21 %) were predictors of an AE-
IPF (HR [95 % CI], 3.35 [1.27–8.84], 2.49 [1.00–6.19], 3.88
[1.54–9.80], 3.17 [1.21–8.31], and 3.27 [1.29–8.29], re-
spectively). In the Cox analysis adjusted for treatment with
an immunosuppressive agent, baseline cardiovascular
diseases, higher GAP stage (≥II), and higher eosinophil
percentage (≥3.21 %) in BAL fluid samples were predictors
of an AE-IPF (HR [95 % CI], 3.21 [1.24–8.32], 3.23
[1.22–8.51], and 2.89 [1.11–7.51], respectively) (Table 3).
Prognostic factors for overall survival from the initial IPF
diagnosis
In the unadjusted Cox analysis, higher baseline GAP
stage (≥II), higher serum SP-D level (≥194.7 ng/mL), and
higher eosinophil percentage (≥3.21 %) in BAL fluid
samples were significant prognostic factors for IPF (HR
[95 % CI], 4.02 [1.68–9.64], 3.49 [1.36–8.94], and 2.42
[1.03–5.68], respectively). In the Cox analysis adjusted
for treatment with an immunosuppressive agent, base-
line cardiovascular diseases, higher GAP stage (≥II), and
higher serum SP-D level (≥194.7 ng/mL) were significant
prognostic factors for IPF (HR [95 % CI], 2.37 [1.03–5.44],
3.63 [1.47–8.93], and 3.21 [1.21–8.48]) (Table 4).
Discussion
This study examined associations between patient char-
acteristics, serum markers, and BAL fluid cellular con-
stituents and the incidence of AE-IPF and survival in a
cohort of IPF patients who were diagnosed based on the
official 2011 IPF ATS/ERS/JRS/ALAT Update Statement
[2]. A log-rank test showed that treatment with an im-
munosuppressive agent after diagnosis, baseline cardio-
vascular diseases, higher GAP stage (≥II), higher serum
LDH level (≥180 U/L), higher serum SP-D level
(≥194.7 ng/mL), and higher neutrophil (≥1.77 %) and eo-
sinophil (≥3.21 %) percentages in BAL fluid samples
were associated with poor AE-free probability. In the
Cox analysis adjusted for treatment with an immunosup-
pressive agent, baseline cardiovascular diseases, higher
GAP stage (≥II), and a higher eosinophil percentage
(≥3.21 %) in BAL fluid samples were predictors of an
AE-IPF.
It was reported that the human lung microbiome and
any changes in its numbers and composition play im-
portant roles in the pathogenesis and progression of
lung diseases, including IPF [17, 18]. In addition, it was
recently reported that patients with IPF had a higher
bacterial load in BAL fluid compared with control sub-
jects and that an increased bacterial load at the time of
diagnosis identified patients with more rapidly progres-
sive IPF and those at a higher risk of mortality [19]. The
multicenter PANTHER trial found that combination
therapy (prednisone, azathioprine, and N-acetylcysteine)
was associated with more AEs than a placebo. [20]. The
Fig. 1 Incidence of acute exacerbation of idiopathic pulmonary fibrosis. The Kaplan-Meier curve demonstrates that the 1-year, 2-year, and 3-year
incidences of AE-IPF were 9.6, 19.2 and 31.0 %, respectively
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Table 1 Comparisons of baseline characteristics between patients with and without an acute exacerbation
Non-AE AE P Value a
(N = 41) (N = 24)
Age, median (IQR), y 69.0 (62.0 to 73.0) 68.0 (62.0 to 73.5) 0.995
Sex, No. (%)
Men 31 (75.6) 20 (83.3) 1.000
Women 10 (24.4) 4 (16.7)
Smoking, No. (%)
S 7 (17.1) 3 (12.5) 1.000
Ex 25 (61.0) 17 (70.8)
N 9 (22.0) 4 (16.7)
Smoking index, pack-years 35.8 (1.0 to 52.3) 31.3 (15.0 to 50.0) 0.940
Cardiovascular diseases, No. (%)
Yes 10 (24.4) 8 (33.3) 1.000
No 31 (75.6) 16 (66.7)
Atopic diseases, No. (%)
Yes 3 (7.3) 1 (4.2) 1.000
No 38 (92.7) 23 (95.8)
Baseline pulmonary function
VC, median (IQR), % predicted 81.0 (64.1 to 95.0) 69.2 (59.5 to 83.0) 0.074
FVC, median (IQR), % predicted 80.4 (59.0 to 93.9) 70.5 (59.9 to 82.1) 0.055
TLC, median (IQR), % predicted 75.9 (63.0 to 90.0) 66.1 (54.0 to 77.0) 0.020
DLCO, median (IQR), % predicted 58.0 (46.1 to 72.5) 46.2 (41.0 to 72.3) 0.276
KCO, median (IQR), % predicted 69.5 (60.8 to 85.0) 73.0 (57.7 to 78.0) 0.866
GAP stage, No. (%)
I 25 (69.4) 10 (45.5) 1.000
II 9 (25.0) 12 (54.5)
III 2 (5.6) 0 (0.0)
CPI 37.3 (22.2 to 47.6) 47.7 (30.5 to 54.9) 0.190
Respiratory parameters b
PaO2, median (IQR), mm Hg 80.7 (75.3 to 91.0) 81.0 (75.2 to 94.5) 0.810
A-a DO2, median (IQR), mm Hg 17.5 (3.8 to 26.2) 17.2 (4.1 to 25.2) 0.889
Hematologic data
WBC, median (IQR),/mm3 6700 (5800 to 8100) 7350 (5750 to 9300) 0.442
Neutrophils, median (IQR), % 62.8 (57.0 to 69.4) 63.9 (58.0 to 69.0) 0.897
Eosinophils, median (IQR), % 3.0 (2.0 to 4.7) 2.9 (1.8 to 4.4) 0.545
Serum markers
CRP, median (IQR), mg/dL 0.31 (0.06 to 0.69) 0.29 (0.13 to 0.64) 0.688
LDH, median (IQR), U/L 235 (187.0 to 255.0) 247 (223.5 to 296.0) 0.082
KL-6, median (IQR), U/mL 912 (595.0 to 1802.0) 1258 (744.5 to 2006.0) 0.246
SP-D, median (IQR), ng/mL 203 (131.0 to 342.0) 269 (178.6 to 343.0) 0.285
BAL fluid findings
Total cell count, median (IQR), ×105/mL 2.50 (1.40 to 3.67) 3.21 (2.22 to 3.97) 0.099
Macrophages, median (IQR), % 80.2 (62.5 to 88.9) 76.6 (67.3 to 84.8) 0.492
Lymphocytes, median (IQR), % 6.8 (3.9 to 11.4) 11.6 (3.2 to 17.1) 0.649
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present study also demonstrated that treatment with an
immunosuppressive agent was associated with an AE-
IPF in the log-rank test and unadjusted Cox analysis. In
addition, Papiris et al. recently reported that immuno-
suppression adversely affected the outcomes of AE-IPFs
[21]. These findings imply that treatment with an im-
munosuppressive agent may increase the bacterial load
in the lungs of patients with IPF and lead to an AE-IPF.
Further studies are needed to elucidate the association
between bacterial load and AE-IPFs. However, baseline
cardiovascular diseases, higher GAP stage (≥II), and
higher eosinophil percentage (≥3.21 %) in BAL fluid
samples were predictors of an AE-IPF, even after adjust-
ment for treatment with an immunosuppressive agent in
the Cox analysis. These risk factors were thought to be
independent of treatment with an immunosuppressive
agent.
BAL fluid analyses in IPF patients typically show an in-
crease in total cell count, neutrophils (>5 %), and eosino-
phils (>5 %) [22]. In the present study, baseline median
neutrophil and eosinophil percentages in the BAL fluid
of patients who experienced an AE were 7.0 % (IQR:
3.2–10.5 %) and 4.6 % (IQR: 2.1–7.0 %), respectively.
These BAL fluid findings were consistent with those pre-
viously reported in patients with IPF [22]. This study
showed that higher neutrophil (≥1.77 %) and eosinophil
(≥3.21 %) percentages in BAL fluid samples were associ-
ated with poor AE-free probability in the log-rank test.
In the adjusted Cox analysis, a higher baseline eosinophil
percentage (≥3.21 %) in BAL fluid samples was a pre-
dictor of an AE-IPF. Relative increases in eosinophil and
neutrophil percentages in BAL fluid may identify a sub-
set of patients with disease that is more “active” or in an
accelerated phase of tissue damage that may predispose
them to an AE. Although inflammation is never a prom-
inent histopathological finding in UIP [2], occult sus-
tained eosinophil and neutrophil accumulations in the
alveolar space may be key immune effector cells driving
the inflammatory response and may play a role in the
occurrence of an AE-IPF. Findings of recent studies of
high BAL fluid eosinophil and neutrophil percentages in
patients with IPF during AEs lend support to this possi-
bility [3, 9]. Tabuena et al. [23] found that BAL fluid
neutrophil and lymphocyte counts predicted mortality in
current smokers in a study of 81 patients with IPF. Kin-
der et al. recently reported that each doubling of
Table 1 Comparisons of baseline characteristics between patients with and without an acute exacerbation (Continued)
Neutrophils, median (IQR), % 6.7 (2.9 to 13.3) 7.0 (3.2 to 10.5) 0.807
Eosinophils, median (IQR), % 3.3 (1.2 to 5.4) 4.6 (2.1 to 7.0) 0.259
CD4/8 ratio, median (IQR) 1.90 (0.86 to 3.70) 1.10 (0.60 to 1.90) 0.065
Treatment after the diagnosis
Steroid, No. (%)
yes 7 (17.1) 8 (33.3) 1.000
No 34 (82.9) 16 (66.7)
Immunosuppressive agent c, No. (%)
Yes 3 (7.3) 6 (25.0) 1.000
No 38 (92.7) 18 (75.0)
Steroid with immunosuppressive agent, No. (%)
Yes 3 (7.3) 5 (20.8) 1.000
No 38 (92.7) 19 (79.2)
Pirfenidone, No. (%)
Yes 8 (19.5) 6 (25.0) 1.000
No 33 (80.5) 18 (75.0)
NAC, No. (%)
Yes 8 (19.5) 5 (20.8) 1.000
No 33 (80.5) 19 (79.2)
Abbreviations: AE acute exacerbation, N number of patients, IQR interquartile range, S/Ex/N current smoker/ex-smoker/nonsmoker, VC vital capacity, FVC forced
vital capacity, TLC total lung capacity, DLCO diffusing capacity for carbon monoxide, KCO carbon monoxide transfer coefficient, GAP gender-age-physiology, CPI
composite physiologic index, P/F ratio PaO2/fraction of inspired oxygen ratio, A-a DO2 alveolar-arterial difference in oxygen, WBC white blood cell count,
CRP C-reactive protein, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D, BAL bronchoalveolar lavage, CD4/8 ratio
CD4/CD8 lymphocyte subset ratio, NAC inhaled N-acetylcysteine
Data are presented as the median (interquartile range)
aWilcoxon’s rank-sum test was performed for continuous variables, and Fisher’s exact test was performed for categorical variables
bOne patient in the Non-AE group required oxygen (1 L/min O2 via a nasal cannula) at the time of sample collection. All other results were obtained at room air
cImmunosuppressive agents included cyclosporine (N = 7) and cyclophosphamide (N = 2)
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baseline BAL fluid neutrophil percentage was associated
with a 30 % increase in mortality risk in a series of 156
patients with biopsy-proven IPF [24]. These observations
also suggest the potential contribution of inflammation
in the pathogenesis of IPF. Although the possible role of
a chronic inflammatory response has been largely
neglected because of the inefficacy of corticosteroids and
immunosuppressants in the treatment of IPF [2, 20], fur-
ther studies focusing on the potential role of inflamma-
tion in IPF pathogenesis and AE-IPF occurrence are
needed. Current practice and consensus guidelines [2]
do not recommend performing BAL for a determination
of cellular constituents in BAL fluid at the time of IPF
diagnosis. However, the indication for BAL with a cellu-
lar analysis may become clearer when effective therapies
to prevent an AE-IPF are discovered.
This study showed that a baseline higher GAP stage
(≥II) was one of the predictors of an AE-IPF and a sig-
nificant prognostic factor for IPF in the adjusted Cox
analysis. This GAP model consists of four baseline
variables: gender (G), age (A), and two lung physiology
variables (P) (FVC and diffusing capacity for carbon
monoxide) [12]. It has been proposed that the GAP
model was useful in the prediction of mortality at base-
line in patients with IPF [12]. In addition, it was re-
ported that GAP stage III IPF patients tended to have a
higher incidence of AEs than stage II and stage I patients
[25]. The present findings along with those obtained in
previous studies suggest that the GAP staging system
could be used as a quick and simple screening method
for predicting AE-IPF.
Cardiovascular disease has been reported to be one of
the most frequently observed comorbidities in patients
with IPF and associated with shortened survival time
[26, 27]. However, the impact on AE-IPF has remained
unknown. This study showed that baseline cardiovascu-
lar disease was not only a prognostic factor for IPF, but
also a risk factor for an AE-IPF in the adjusted Cox ana-
lysis. Further studies are needed to elucidate the mecha-
nisms of why cardiovascular disease increases the risk of
AE-IPF.
SP-D is a lipoprotein complex synthesized mainly by
alveolar type II epithelial cells and is secreted into a li-
quid layer lining the lung epithelium. Increased serum
SP-D levels obtained at the time of IPF diagnosis were
reported to be associated with increased mortality
[28–30]. In the present study, serum SP-D levels ob-
tained at the time of initial diagnosis were associated
with AE-free probability in a log-rank test and overall
survival in the adjusted Cox analysis. Two mecha-
nisms may contribute to elevated SP-D serum levels in
pulmonary fibrosis: (1) an absolute increase in alveolar
type II epithelial cells due to diffuse hyperplasia increases
at the source of pulmonary SP-D; and (2) epithelial injury
and basal membrane leakage may cause spillover into the
circulation [28]. Evidence indicates that repetitive injuries
to alveolar epithelial cells trigger an exaggerated wound
healing response resulting in extensive scar formation,
Fig. 2 Impact of acute exacerbation on overall survival. There was a significant difference in survival between patients who experienced an acute
exacerbation (median survival time, 2.8 years) and those who did not (median survival time, not calculable) (log-rank test, P < 0.001)
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and finally, pulmonary fibrosis [31, 32]. Together with pre-
vious observations, the present findings suggest that injur-
ies to alveolar epithelial cells may be one of the important
triggers for IPF progression.
In a randomized trial of pirfenidone, a positive treat-
ment effect was demonstrated, including fewer AE-IPF
episodes (14 % versus none) [33]. However, a previous
study did not reproduce the inhibitory effect of pirfeni-
done on AE-IPF [34]. In the present study, neither treat-
ment with pirfenidone nor N-acetylcysteine was
associated with AE-free probability in a log-rank test.
However, this might be due to the small number of pa-
tients treated with pirfenidone or NAC in this study.
Table 2 Log-rank test for risk factors for an acute exacerbation
of idiopathic pulmonary fibrosis
Non-AE (N = 41) AE (N = 24) log-rank P Value
Smoking
S or Ex 32 20 0.918
N 9 4
Cardiovascular diseases
Yes 10 8 0.042
No 31 16
GAP stage




≥ 180 32 22 0.048
< 180 9 2
KL-6
≥ 946 18 16 0.292
< 946 21 8
SP-D
≥ 194.7 22 18 0.014
< 194.7 17 6
BAL fluid findings
Lymphocytes
≥ 10.15 13 13 0.085
< 10.15 28 11
Neutrophils
≥ 1.77 34 22 0.048
< 1.77 7 2
Eosinophils
≥ 3.21 21 17 0.009
< 3.21 20 7
Treatment after the diagnosis
Steroid
Yes 7 8 0.443
No 34 16
Immunosuppressive agent
Yes 3 6 0.009
No 38 18
Pirfenidone
Yes 8 6 0.963
No 33 18
NAC
Yes 8 5 0.547
No 33 19
Abbreviations: AE acute exacerbation, N number of patients, S/Ex/N current
smoker/ex-smoker/nonsmoker, GAP gender-age-physiology, LDH lactate
dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D, BAL
bronchoalveolar lavage, NAC inhaled N-acetylcysteine
Table 3 Cox analysis for risk factors for an acute exacerbation of
idiopathic pulmonary fibrosis
HR (95 % CI) P Value
Treatment after the diagnosis
Immunosuppressive agent
Unadjusted 3.35 (1.27 to 8.84) 0.014
Cardiovascular diseases
Unadjusted 2.49 (1.00 to 6.19) 0.049
Adjusteda 3.21 (1.24 to 8.32) 0.016
GAP stage (≥II)
Unadjusted 3.88 (1.54 to 9.80) 0.004
Adjusteda 3.23 (1.22 to 8.51) 0.018
Serum markers
LDH, U/L, Cut off point = 180
Unadjusted 4.00 (0.92 to 17.46) 0.065
Adjusteda 3.49 (0.78 to 15.57) 0.101
KL-6, U/mL, Cut off point = 946
Unadjusted 1.57 (0.67 to 3.68) 0.296
Adjusteda 1.53 (0.65 to 3.59) 0.326
SP-D, ng/mL, Cut off point = 194.7
Unadjusted 3.17 (1.21 to 8.31) 0.019
Adjusteda 2.69 (0.98 to 7.42) 0.056
BAL fluid findings
Lymphocytes, %, Cut off point = 10.15
Unadjusted 2.01 (0.89 to 4.52) 0.091
Adjusteda 2.03 (0.90 to 4.57) 0.087
Neutrophils, %, Cut off point = 1.77
Unadjusted 4.04 (0.92 to 17.79) 0.065
Adjusteda 3.54 (0.79 to 15.94) 0.100
Eosinophils, %, Cut off point = 3.21
Unadjusted 3.27 (1.29 to 8.29) 0.013
Adjusteda 2.89 (1.11 to 7.51) 0.029
Abbreviations: HR hazard ratio, CI confidence interval, GAP gender-age-
physiology, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D
surfactant protein-D, BAL bronchoalveolar lavage
aAdjusted for immunosuppressive agent therapy
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Whether new antifibrotic agents have preventive effects
against AE-IPF is an interesting clinical question. Fur-
ther studies are needed to elucidate this question.
Previously reported conflicting results regarding risk
factors for an AE-IPF were probably partly related to the
use of multiple AE-IPF definitions. According to previ-
ously reported AE-IPF criteria, endotracheal aspirate or
BAL fluid should be examined to exclude pulmonary
infection, and patients who do not undergo these proce-
dures should be termed as having a “suspected AE” [4].
However, these procedures are often not feasible given
the significant hypoxemia typical in an AE-IPF. There is
a frequent inability to exclude underlying infection
results confidently in a large number of “suspected” AE-
IPF cases that cannot be confirmed. Therefore, the def-
inition of AE-IPF in the present study did not include
the performance of endotracheal aspirate collection or
BAL as an essential component. Collard et al. recently
reported that suspected AE-IPF cases were clinically in-
distinguishable from definite AE-IPF cases, and were as-
sociated with similarly high risks of disease progression
and short-term mortality in IPF [35]. Ryerson et al. re-
cently proposed expanding the AE-IPF diagnostic cri-
teria by allowing the diagnostic criteria to be met
without the performance of invasive procedures (e.g.
bronchoscopy) [36]. In fact, the definition of AE-IPF
used in recent clinical trials of nintedanib did not in-
clude the performance of endotracheal aspirate collec-
tion or BAL as essential components, and infection was
excluded in accordance with routine clinical practice
and microbiologic studies [37]. Therefore, the results ob-
tained in the present study are thought to be practical
for the management of patients with IPF in daily clinical
settings.
There are some limitations to this study. First, this was
a retrospective study with a small number of subjects.
Because of the small numbers of AEs and deaths, risk
factors and prognostic factors were adjusted only by
treatment with an immunosuppressive agent in the mul-
tiple Cox analysis. Because the associations among sev-
eral factors seem to be complex, further study in a larger
patient cohort is needed to analyze independent risk fac-
tors for AE-IPF and prognostic factors for IPF. Second,
although the present study suggests that alveolar inflam-
mation may be one of the key pathways activated prior
to the development of an AE-IPF, the precise biological
mechanisms of AE-IPF remain unknown. Third, this
study included only Japanese patients. Therefore, further
studies are needed to ascertain whether these results can
be applied equally to other ethnic groups. The relative
rarity of AE-IPF suggests that these research questions
should be answered by multicenter collaborations.
Conclusions
In conclusion, this study demonstrated that baseline car-
diovascular diseases, higher GAP stage (≥II), and higher
eosinophil percentage (≥3.21 %) in BAL fluid samples
were predictors of an AE-IPF. Further studies are needed
to elucidate the association between these markers and
mechanisms of AE occurrence.
Abbreviations
A-a DO2, alveolar-arterial difference in oxygen; AE, acute exacerbation; BAL,
bronchoalveolar lavage; CI, confidence interval; CPI, composite physiologic
index; CRP, C-reactive protein; DLCO, diffusing capacity for carbon monoxide;
FiO2, fraction of inspired oxygen; FVC, forced vital capacity; GAP, gender-age-
physiology; HR, hazard ratio; HRCT, high-resolution computed tomography;
IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; KCO, carbon
Table 4 Cox analysis for prognostic factors for overall survival
from the idiopathic pulmonary fibrosis initial diagnosis
HR (95 % CI) P Value
Treatment after diagnosis
Immunosuppressive agent
Unadjusted 2.40 (0.96 to 6.02) 0.062
Cardiovascular diseases
Unadjusted 2.08 (0.91 to 4.54) 0.086
Adjusteda 2.37 (1.03 to 5.44) 0.042
GAP stage (≥II)
Unadjusted 4.02 (1.68 to 9.64) 0.002
Adjusteda 3.63 (1.47 to 8.93) 0.005
Serum markers
LDH, U/L, Cut off point = 180
Unadjusted 2.49 (0.74 to 8.37) 0.139
Adjusteda 2.24 (0.66 to 7.63) 0.198
KL-6, U/mL, Cut off point = 946
Unadjusted 1.46 (0.67 to 3.18) 0.340
Adjusteda 1.45 (0.67 to 3.17) 0.345
SP-D, ng/mL, Cut off point = 194.7
Unadjusted 3.49 (1.36 to 8.94) 0.009
Adjusteda 3.21 (1.21 to 8.48) 0.019
BAL fluid findings
Lymphocytes, %, Cut off point = 10.15
Unadjusted 1.96 (0.93 to 4.14) 0.077
Adjusteda 1.99 (0.94 to 4.21) 0.072
Neutrophils, %, Cut off point = 1.77
Unadjusted 2.48 (0.73 to 8.45) 0.147
Adjusteda 2.21 (0.63 to 7.69) 0.213
Eosinophils, %, Cut off point = 3.21
Unadjusted 2.42 (1.03 to 5.68) 0.043
Adjusteda 2.20 (0.92 to 5.25) 0.075
Abbreviations: HR hazard ratio, CI confidence interval, GAP gender-age-
physiology, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D
surfactant protein-D, BAL bronchoalveolar lavage
aAdjusted for immunosuppressive agent therapy
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monoxide transfer coefficient; KL-6, Krebs von den Lungen-6; LDH, lactate de-
hydrogenase; MST, median survival time; NAC, N-acetylcysteine; P/F ratio, par-
tial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen
(FiO2) ratio; PaO2, partial pressure of oxygen in arterial blood; ROC, receiver
operating characteristic; SP-D, surfactant protein-D; UIP, usual interstitial
pneumonia
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